GDTC
CytoMed Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · SG
$0.85
−6.59%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.83
From 52W high−59.72%
Volume1437.00
Market cap$10.14M
P/E (TTM)—
P/S (TTM)18.0x
Div yield—
Key dataNov 4, 2026
Open
$0.83
From 52W high
−59.72%
Volume
1437.00
Market cap
$10.14M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
P/E (TTM)
—
RSI (14)
43.6
MomentumView details →
1D Return
−6.59%
YTD Return
−36.57%
SummaryUpdated Jun 1, 2026
CytoMed Therapeutics Limited (NASDAQ:GDTC) is a Singapore-based pre-clinical biopharmaceutical company founded in 2018 that specializes in developing novel cell-based immunotherapies for cancer treatment. The company went public in April 2023 and focuses on harnessing the power of gamma delta T cells and other immune cells to create innovative cancer treatments. As a pre-clinical stage company, CytoMed is currently developing its pipeline of experimental therapies without any approved products on the market.
Similar companies
Latest newsMore news →
No recent news for GDTC.